FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Camber Capital Management LP
2. Issuer Name and Ticker or Trading Symbol

AMAG PHARMACEUTICALS, INC. [ AMAG ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

101 HUNTINGTON AVENUE, SUITE 2101
3. Date of Earliest Transaction (MM/DD/YYYY)

10/1/2020
(Street)

BOSTON, MA 02199
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/1/2020 10/1/2020 S  4390000 D$13.5733 0 I See Footnotes (1)(2)(3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) Securities reported herein for Camber Capital Management LP (the "LP" ) represent Common Stock beneficially owned and held of record by Camber Capital Master Fund, L.P. (the "Master Fund") and another private investment fund (the "Fund") for which the LP serves as the investment manager. Stephen DuBois is the managing member of the LP and managing member of the general partner for the Fund and the Master Fund. The LP, the Master Fund, the Fund, the general partner and Mr. DuBois (the "Reporting Persons") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 21, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein.
(2) Of the securities reported for this transaction, 4,361,316 shares of Common Stock were sold for the account of the Master Fund and 28,684 shares of Common Stock were sold for the account of the Fund
(3) As of the closing of trading on October 01, 2020, 0 shares of Common Stock were held for the account of the Master Fund and 0 shares of Common Stock were held for the account of the Fund.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Camber Capital Management LP
101 HUNTINGTON AVENUE
SUITE 2101
BOSTON, MA 02199

X


Signatures
/s/ Stephen DuBois10/5/2020
**Signature of Reporting PersonDate

AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more AMAG Pharmaceuticals Charts.
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more AMAG Pharmaceuticals Charts.